Sugi Predict

Sugi Predict / Compounds / SCHEMBL1448464

SCHEMBL1448464

SCHEMBL1448464

c1ccc(Nc2nccc(-c3ncc[nH]3)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK1 P06493 2/20 0.56
▸ CCNB2 O95067 1/20 0.56
▸ CCNB1 P14635 1/20 0.56
▸ CCNB3 Q8WWL7 1/20 0.56
▸ PRKCD Q05655 2/20 0.55
▸ ABL1 P00519 1/20 0.55
▸ EGFR P00533 1/20 0.55
▸ PRKCA P17252 1/20 0.55
▸ CDK2 P24941 4/20 0.53
▸ CDK4 P11802 3/20 0.53
▸ IKBKB O14920 4/20 0.53
▸ CHEK1 O14757 1/20 0.53
▸ AURKA O14965 1/20 0.53
▸ NPC1 O15118 1/20 0.53
▸ PDPK1 O15530 1/20 0.53
▸ CHEK2 O96017 1/20 0.53
▸ PRKCG P05129 1/20 0.53
▸ LYN P07948 1/20 0.53
▸ MAPT P10636 1/20 0.53
▸ KIT P10721 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4558120 0.85 CDK1 (0.55) CDK1CCNB2CCNB1CCNB3ABL1
SCHEMBL7463899 0.79 SYK (0.57) CDK1CCNB2CCNB1CCNB3PRKCD
SCHEMBL1593016 0.77 PRKCD (0.79) CDK1CCNB2CCNB1CCNB3PRKCD
SCHEMBL6420569 0.76 PRKCD (0.55) CDK1CCNB2CCNB1CCNB3PRKCD
SCHEMBL7470857 0.74 ABL1 (0.63) CDK1CCNB2CCNB1CCNB3PRKCD
SCHEMBL3626716 0.74 PRKCD (0.59) CDK1CCNB2CCNB1CCNB3PRKCD
SCHEMBL6662596 0.74 CDK2 (0.49) CDK1PRKCDABL1EGFRPRKCA
SCHEMBL4029958 0.73 ABL1 (0.72) CDK1PRKCDABL1EGFRPRKCA
SCHEMBL1448466 0.73 CDK1 (0.56) CDK1CCNB2CCNB1CCNB3PRKCD
SCHEMBL27116599 0.73 ABL1 (0.62) CDK1CCNB2CCNB1CCNB3PRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2170849-B1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LTD (GB) 2016-12-21 — — EP disclosed
US-9187465-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2015-11-17 — — US disclosed
US-20150057282-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2015-02-26 — — US disclosed
US-8921544-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2014-12-30 — — US disclosed
US-20140275041-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2014-09-18 — — US disclosed
US-20130102592-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2013-04-25 — — US disclosed
US-8378095-B2 Oxazole tyrosine kinase inhibitors Saruem Limited (GB) 2013-02-19 — — US disclosed
EP-2301928-A1 Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders AstraZeneca AB (SE) 2011-03-30 — — EP disclosed
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2010-11-25 — — US disclosed
EP-2044058-B1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2010-09-29 — — EP disclosed
US-20070161615-A1 Chemical compounds ASTRAZENECA AB (SE) 2007-07-12 — — US disclosed
CN-1938295-A Imidazol-5-yl-anilinopyrimidines as cell proliferation inhibitors ASTRAZENECA AB (SE) 2007-03-28 — — CN disclosed
WO-2007015064-A1 IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2007-02-08 — — WO disclosed
EP-1748999-A1 IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION AstraZeneca AB (SE) 2007-02-07 — — EP disclosed
US-20060229329-A1 Pyrimidine derivatives possessing cell-cycle inhibitors activity ASTRAZENECA AB (SE) 2006-10-12 — — US disclosed
WO-2006095159-A1 (IMIDAZOLO-5-YL)-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION ASTRAZENECA AB (SE) 2006-09-14 — — WO disclosed
WO-2006064251-A1 4- (4- (IMIDAZOL-4-YL) PYRIMIDIN-2-YLAMINO) BENZAMIDES AS CDK INHIBITORS ASTRAZENECA AB (SE) 2006-06-22 — — WO disclosed
EP-1636227-A1 PYRIMIDINE DERIVATIVES POSSESSING CELL-CYCLE INHIBITORY ACTIVITY Astrazeneca AB (SE) 2006-03-22 — — EP disclosed
WO-2005075461-A1 IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION ASTRAZENECA AB (SE) 2005-08-18 — — WO disclosed
WO-2004101564-A1 PYRIMIDINE DERIVATIVES POSSESSING CELL-CYCLE INHIBITORY ACTIVITY ASTRAZENECA AB (SE) 2004-11-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229329-A1 Pyrimidine derivatives possessing cell-cycle inhibitors activity TYMP, CCNI, MKI67 CDK1 28/4885CCNB2 26/4885CCNB1 10/4885
US-20070161615-A1 Chemical compounds MKI67, PCNA, CCNI CDK1 31/4885CCNB2 13/4885CCNB1 12/4885
US-20140275041-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 CDK1 14/4885CCNB2 238/4885CCNB1 177/4885
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 CDK1 14/4885CCNB2 238/4885CCNB1 177/4885
US-20150057282-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 CDK1 14/4885CCNB2 238/4885CCNB1 177/4885
US-20130102592-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 CDK1 17/4885CCNB2 261/4885CCNB1 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.